The place of taxanes in ovarian cancer

teaser

MT Huizing
MD PhD
Academic Medical Oncologist

JB Vermorken
MD PhD
Professor of Oncology
and Head
Department of Medical Oncology
University Hospital Antwerp, Edegem
Belgium
E:[email protected]

Ovarian epithelial cancer is the most lethal of the gynaecological malignancies, affecting approximately 1 in 75 women in the developed world. In most cases (>75%), the disease has extended beyond the ovary at diagnosis. For over 30 years, chemotherapy has been incorporated into the treatment of ovarian cancer, both in the adjuvant setting and for the management of advanced disease.

Cisplatin and its second-generation analogue carboplatin are considered the most active chemotherapeutic agents in ovarian cancer and have been incorporated in most clinical trials. They offer superior survival compared with the same regimens without platinum.(1–3)

In the late 1980s and early 1990s taxanes were introduced as a new class of antineoplastic drugs, with paclitaxel and docetaxel as the main representatives.(4,5) Early clinical trials showed promising activity of both paclitaxel and docetaxel against heavily pretreated, platinum-refractory ovarian cancer.(4,5)

Paclitaxel
As a single agent paclitaxel induces a response rate of  37% with a median duration of response of 4.2 months, and a median survival of 16 months in recurrent epithelial ovarian cancer.(6)

A large four-arm factorial randomised study, the so called OV-9 study, compared two dosage levels (175mg/m(2) versus 135mg/m(2)) and two infusion durations (three-hour versus 24-hour), in an attempt to optimise the administration schedule of the drug. Response rate was slightly higher with the 175mg/m(2) dose (20%) than with 135 mg/m(2) dose (15%), but this was not statistically significant (p=0.2). However, progression-free survival was significantly longer in the high-dose group (19 vs 14 weeks; p=0.02). The results of this trial have led to the three-hour 175mg/m(2) paclitaxel schedule being considered standard treatment for relapsed ovarian cancer in Western Europe.(7)

Soon thereafter, paclitaxel was studied in prospective randomised clinical trials as firstline therapy. The first reported trial was that of the Gynecologic Oncology Group (protocol GOG-111), which showed superior efficacy of the combination of paclitaxel (135mg/m(2); 24h)/cisplatin (75mg/m(2)) over cyclophosphamide (600mg/m(2))/cisplatin (75mg/m(2)) in chemo-naive, suboptimally debulked ovarian cancer patients with respect to response rate, disease-free survival and overall survival. In fact an absolute gain of 11% in overall survival was reported.(8)

A European-Canadian intergroup study (OV-10), which unlike GOG-111 also included optimally debulked disease patients, again reported highly consistent results in terms of response, time to progression and overall survival.(9) These results were so impressive that the paclitaxel/cisplatin combination was accepted as the new standard for frontline chemotherapy in patients with advanced ovarian cancer. (10,11)

Nevertheless, the schedule with 24-hour paclitaxel (GOG-111) was felt to be unpractical and the schedule with three-hour paclitaxel (OV-10) too neurotoxic. Therefore when three randomised trials comparing three-hour paclitaxel/carboplatin with three-hour paclitaxel/cisplatin showed comparable efficacy (at least in terms of response and progression-free survival), but much better tolerance for the carboplatin-based regimen, this was adopted by many clinicians as the new standard in daily practice.(11–13)

Recently, two negative randomised trials have been reported, GOG-132 and ICON-3.(14,15) These two studies failed to show a significant survival benefit of the combination paclitaxel/platinum compared with optimally dosed platinum alone.

At present the conflicting results of these four randomised trials (GOG-111, OV-10, GOG-132 and ICON-3) are a matter of debate.(16)

Docetaxel
The role of paclitaxel in ovarian cancer is solely based on historical grounds, ie, it was the first taxane to be used in the treatment of ovarian cancer. However, there is now substantial evidence to suggest that docetaxel (100mg/m(2) every three weeks) used as a single agent in patients failing platinum-based therapies might yield the same efficacy as paclitaxel.(17) Moreover, in-vitro data demonstrate a lack of complete cross-resistance between docetaxel and paclitaxel. As a result, antitumour activity has also been demonstrated in patients refractory to a paclitaxel-containing regimen.(18) The Scottish Randomized Trial in Ovarian Cancer (SCOTROC) randomly assigned 1,077 chemonaive patients with International Federation of Gynecology and Obstetrics (FIGO) stage Ic–IV disease to either six cycles of docetaxel/ carboplatin (75mg/m(2), 1h/AUC 5) or paclitaxel/carboplatin (175mg/m(2), 3h/AUC 5).(19) Both progression-free survival and overall survival were equivalent with the two regimens. However, the observed toxicities were different. Myelosuppression occurred more frequently and/or was more serious with docetaxel/ carboplatin and neuropathy was more common with paclitaxel/carboplatin; in fact, more patients stopped paclitaxel/carboplatin because of neurotoxicity during chemotherapy. Quality-of-life analyses highlighted differences that favoured the docetaxel/carboplatin treatment arm. Additional SCOTROC studies using docetaxel are ongoing. These early data suggest that for some patients docetaxel/carboplatin might represent a reasonable alternative to paclitaxel/carboplatin as a firstline option for newly diagnosed epithelial ovarian cancer.

Intraperitoneal treatment of paclitaxel
Intraperitoneal chemotherapy with paclitaxel for the treatment of patients with epithelial ovarian cancer is theoretically an attractive approach taking into account the biology of the disease, the physiological and anatomical characteristics of the peritoneal cavity, and the pharmacological advantage of paclitaxel when administered intraperitoneally (1,000-fold increase in exposure) compared with intravenously.(20,21)

Several randomised trials of firstline intraperitoneal chemotherapy in patients with small-volume residual ovarian cancer after primary surgical cyto-reduction have reported a survival advantage with regional drug delivery.(20)

With respect to the role of paclitaxel in this approach two studies have to be mentioned. First, a phase II trial in 68 assessable women with optimal stage III ovarian cancer showed a two-year survival rate of 91%, and a median survival of 51 months. The two-year disease-free survival rate was 66%, and median disease-free survival was 33 months.(22)

Second, the potential role of intraperitoneal paclitaxel has also been evaluated in protocol GOG-172.(23) In this study, patients with optimal stage III ovarian cancer were randomised between intravenous paclitaxel (135mg/m(2), 24h)/cisplatin (75mg/m(2)) and intravenous paclitaxel (135mg/m(2): d1) plus intraperitoneal paclitaxel (80mg/m(2): d8) in combination with intraperitoneal cisplatin (100mg/m(2): d2). Preliminary results showed an improved progression- free survival for the intraperitoneal arm (24.3 vs 19.3 months: p=0.029) at the expense of more pronounced toxicity. The overall survival data are to be awaited.(23)

Future directions
Paclitaxel/carboplatin has been broadly accepted as the standard arm against which new regimens are evaluated in the design of oncology trials. These studies include trials with topotecan, gemcitabine, liposomal doxorubicin or epirubicin, given either as triplets (+paclitaxel/carboplatin) or as sequential doublets.

Newer agents that target the molecular changes which characterise, and may even control ovarian cancer growth, get major attention. Numerous such targets have been identified in both the cancer cell and the extracellular matrix. Recent examples of new therapeutic approaches in clinical trials include epidermal growth factor receptor (EGFR) inhibitors, and therapies involving monoclonal antibodies or monoclonal antibody radioimmunotherapy. Final results of such studies are eagerly awaited.

Real progress can only be expected when a better understanding is achieved of the mechanisms underlying clinical drug resistance in ovarian cancer, and a close laboratory–clinical collaboration will be needed.

[[HPE10_table1_24]]

References

1. Aabo K, Adams M, Adnitt P, et al. Br J Cancer 1998;78:1479-87.
2. Covens A, Carey M, Bryson P, et al. Gynecol Oncol 2002;85:71-80.
3. Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer. In: The Cochrane library of systematic reviews. Issue 4. Oxford: Update Software; 2002.
4. Huizing MT, Sewbarath Misser VH,  et al. Cancer Invest 1995;13:381-404.
5. Eisenhauer EA, Vermorken JB. Drugs 1998;55:5-30.
6. Thigpen JT, Blessing JA, Ball H, et al. J Clin Oncol 1994;12:1748-53.
7. Eisenhauer EA, Ten Bokkel Huinink WW, et al. J Clin Oncol 1995;12:2654-66.
8. McGuire WP, Hoskins WJ, Brady MF, et al. N Eng J Med 1996;334:3-6.
9. Piccart MJ, Bertelsen K, James K, et al. J Natl Cancer Inst 2000;92:699-708.
10. Berek JS, Bertelsen K, duBois A, et al. Ann Oncol 1999;10(Suppl 1):S87-92.
11. Ozols R, Bundy B, Fowler J, et al. [abstract]. Proc Am Soc Clin Oncol 1999;18:356a.
12. DuBois A, Lueck HJ, Meier W, et al. [abstract]. Proc Am Soc Clin Oncol 1999;18:356a.
13. Neijt JP, Engelholm SA, Tuxen MK, et al. J Clin Oncol 2000;18:3084-92.
14. Muggia FM, Braly PS, Brady MF, et al. J Clin Oncol 2000;18:106-15.
15. The International Collaborative Ovarian Neoplasm (ICON) Group. Lancet 2002;360:505-15.
16. Sandercock J, Parmar MKB, Torri V, Qian W. Br J Cancer 2002;87:815-24.
17. Kaye SB, Scottish Gynaecological Cancer Trials Group. Int J Gynecol Cancer 2001;11(Suppl 1):31-3.
18. Benjapibal M, Kudelka AP, Vasuratna A, et al. Anticancer Drugs 1998;9:577-9.
19. Vasey P. [abstract]. Proc Am Soc Clin Oncol 2002;21:202a.
20. Vermorken JB. Int J Gynecol Cancer 2000;10(Suppl 1):26-32.
21. Markman M, Rowinsky E, Hakes T, et al. J Clin Oncol 1992;10:1485-91.
22. Rothenberg ML, Liu PY, Braly PS, et al. J Clin Oncol 2003;21:1313-9.
23. Armstrong DK, Bundy BN, Baergen R, et al. [abstract]. Proc Am Soc Clin Oncol 2002;21:201a.